What were the key findings of the AVITA Medical (ASX:AVH) Cohealyx-I interim study?

AVITA Medical reported that its Cohealyx® product significantly reduced the mean time to skin grafting to 13.6 days, compared to a real-world benchmark of 33.2 days. The study of 40 patients showed that grafting could occur as early as five days, with 72% of patients ready within a fortnight.

Why does the Cohealyx-I study matter for AVITA Medical (ASX:AVH) investors?

These results suggest that Cohealyx could become the new clinical benchmark for treating full-thickness wounds by solving the primary challenge of efficient wound bed preparation.

How did AVITA Medical (ASX:AVH) perform against industry benchmarks?

The study's mean grafting time of 13.6 days outperformed the literature-derived benchmark of 33.2 days, which was based on a meta-analysis of approximately 900 patients using leading dermal matrices.

What is the management strategy for AVITA Medical (ASX:AVH) following this news?

Interim CEO Cary Vance intends to use this data as a "differentiated solution" to drive broader clinical adoption and improve every stage of the wound healing pathway.

What are the main bull and bear points for AVH stock after this announcement?

The bull case rests on the statistically significant p < 0.001 result and high surgeon satisfaction, which suggests a clear path to market leadership in dermal matrices. The bear case remains that these are interim results from a small sample size of only 40 patients.

What are the key risks for investors in AVITA Medical (ASX:AVH) now?

The primary risk is "execution risk" as the company moves from clinical trials to broad commercial implementation. While the interim data is positive, any safety issues or less impressive results in the remaining portion of the study could stall momentum.

AVITA Medical data shows faster wound healing results

Q: What are the key risks for investors in AVITA Medical (ASX:AVH) now?

The primary risk is "execution risk" as the company moves from clinical trials to broad commercial implementation. While the interim data is positive, any safety issues or less impressive results in the remaining portion of the study could stall momentum.

Written by Isaac FrancisPublished Apr. 14 2026Last Updated Apr. 14 2026

AVITA Medical (ASX:AVH) unveiled interim data from its Cohealyx-I multi-centre study, signalling a potential shift in the standard of care for full-thickness wounds.

The results, presented during the American Burn Association annual meeting, demonstrate that the use of Cohealyx accelerates the preparation of wound beds, reducing the mean time to skin grafting to just 13.6 days.

This represents a nearly 20-day improvement over the real-world literature-derived benchmark of 33.2 days, achieving high statistical significance (p < 0.001).

The analysis, which tracked 40 patients, found a median grafting time of 11 days, with some procedures occurring as early as five days post-treatment.

72% of patients were ready for grafting within a fortnight. Clinical investigators reported a 90% satisfaction rate, emphasising the product’s ability to support rapid vascularisation across a myriad of complex wound types.

Derek Bell, MD, Director of the Kessler Burn Centre, noted that efficient wound bed preparation remains a primary challenge in trauma care, and these results suggest Cohealyx could establish a new clinical benchmark.

AVITA Medical's Interim CEO, Cary Vance, expressed confidence that this "differentiated solution" will drive broader adoption by improving critical stages of the healing pathway.